Transvaginal Treatment of Symptomatic Cystocele Grade II-III
NCT ID: NCT02272322
Last Updated: 2017-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2014-06-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
NCT03594175
RECANA OUS - Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK)
NCT07219758
The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain
NCT02746419
Evaluation of the Safety and Efficacy of the ReLARC Inserter During the Insertion Procedure of GYNEFIX Intrauterine Copper Bearing Contraceptive Device with a Follow-up of 3 Years.
NCT05702281
Crux Biomedical Vena Cava Filter Study - United States
NCT01120509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cystocele repair with biomesh soft prolaps and endofast reliant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is between 40 and 90 years old
* Patient has to sign the informed consent form prior to the procedure
* Patient has to agree with the scheduled follow-up visits on month 1, month 6, year 1, year 2 and year 3
* Patient has symptomatic anterior prolapse
Exclusion Criteria
* Patient is pregnant
* Patient has a wish to become pregnant
* Patient is taking Plavix, Sintrom, Marcoumar, Marevan, Brilique, Efient, Ticlid, Xarelto, Eliquis or Pradaxa. If intake is stopped prior to procedure, patient is allowed to be included.
* Patient is taking LMWH in a dose of more than 40 mg/day
* Patient has a life expectancy \< 1 year
* Patient has a known connective tissue disease
* Patient has a history of surgery of the anterior vaginal wall or pelvis
* A scheduled hysterectomy during the index-procedure
40 Years
90 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Slabbaert Koen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Slabbaert Koen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Koen Slabbaert, MD
Role: PRINCIPAL_INVESTIGATOR
RZ Heilig Hart Tienen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RZ Heilig Hart Tienen
Tienen, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCR-11-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.